Cargando…
Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [(18)F]FDG PET/CT
Differentiated thyroid cancer (DTC) represents the most common thyroid cancer histotype. Generally, it exhibits a good prognosis after conventional treatments; nevertheless, about 20% of patients can develop a local recurrence and/or distant metastasis. In one-third of advanced DTC, the metastatic l...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392185/ https://www.ncbi.nlm.nih.gov/pubmed/34441351 http://dx.doi.org/10.3390/diagnostics11081417 |
_version_ | 1783743441805508608 |
---|---|
author | Ferrari, Cristina Santo, Giulia Ruta, Rossella Lavelli, Valentina Rubini, Dino Mammucci, Paolo Sardaro, Angela Rubini, Giuseppe |
author_facet | Ferrari, Cristina Santo, Giulia Ruta, Rossella Lavelli, Valentina Rubini, Dino Mammucci, Paolo Sardaro, Angela Rubini, Giuseppe |
author_sort | Ferrari, Cristina |
collection | PubMed |
description | Differentiated thyroid cancer (DTC) represents the most common thyroid cancer histotype. Generally, it exhibits a good prognosis after conventional treatments; nevertheless, about 20% of patients can develop a local recurrence and/or distant metastasis. In one-third of advanced DTC, the metastatic lesions lose the ability to take up iodine and become radioactive iodine-refractory (RAI-R) DTC. In this set of patients, the possibility to perform localized treatments should always be taken into consideration before the initiation of systemic therapy. In the last decade, some multi-tyrosine kinase inhibitor (MKI) drugs were approved for advanced DTC, impacting on patient’s survival rate, but at the same time, these therapies have been associated with several adverse events. In this clinical context, the role of 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography/computed tomography ([(18)F]FDG PET/CT) in the early treatment response to these innovative therapies was investigated, in order to assess the potentiality of this diagnostic tool in the early recognition of non-responders, avoiding unnecessary therapy. Herein, we aimed to present a critical overview about the reliability of [(18)F]FDG PET/CT in the early predictive response to MKIs in advanced differentiated thyroid cancer. |
format | Online Article Text |
id | pubmed-8392185 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-83921852021-08-28 Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [(18)F]FDG PET/CT Ferrari, Cristina Santo, Giulia Ruta, Rossella Lavelli, Valentina Rubini, Dino Mammucci, Paolo Sardaro, Angela Rubini, Giuseppe Diagnostics (Basel) Review Differentiated thyroid cancer (DTC) represents the most common thyroid cancer histotype. Generally, it exhibits a good prognosis after conventional treatments; nevertheless, about 20% of patients can develop a local recurrence and/or distant metastasis. In one-third of advanced DTC, the metastatic lesions lose the ability to take up iodine and become radioactive iodine-refractory (RAI-R) DTC. In this set of patients, the possibility to perform localized treatments should always be taken into consideration before the initiation of systemic therapy. In the last decade, some multi-tyrosine kinase inhibitor (MKI) drugs were approved for advanced DTC, impacting on patient’s survival rate, but at the same time, these therapies have been associated with several adverse events. In this clinical context, the role of 2-deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography/computed tomography ([(18)F]FDG PET/CT) in the early treatment response to these innovative therapies was investigated, in order to assess the potentiality of this diagnostic tool in the early recognition of non-responders, avoiding unnecessary therapy. Herein, we aimed to present a critical overview about the reliability of [(18)F]FDG PET/CT in the early predictive response to MKIs in advanced differentiated thyroid cancer. MDPI 2021-08-05 /pmc/articles/PMC8392185/ /pubmed/34441351 http://dx.doi.org/10.3390/diagnostics11081417 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Ferrari, Cristina Santo, Giulia Ruta, Rossella Lavelli, Valentina Rubini, Dino Mammucci, Paolo Sardaro, Angela Rubini, Giuseppe Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [(18)F]FDG PET/CT |
title | Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [(18)F]FDG PET/CT |
title_full | Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [(18)F]FDG PET/CT |
title_fullStr | Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [(18)F]FDG PET/CT |
title_full_unstemmed | Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [(18)F]FDG PET/CT |
title_short | Early Predictive Response to Multi-Tyrosine Kinase Inhibitors in Advanced Refractory Radioactive-Iodine Differentiated Thyroid Cancer: A New Challenge for [(18)F]FDG PET/CT |
title_sort | early predictive response to multi-tyrosine kinase inhibitors in advanced refractory radioactive-iodine differentiated thyroid cancer: a new challenge for [(18)f]fdg pet/ct |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392185/ https://www.ncbi.nlm.nih.gov/pubmed/34441351 http://dx.doi.org/10.3390/diagnostics11081417 |
work_keys_str_mv | AT ferraricristina earlypredictiveresponsetomultityrosinekinaseinhibitorsinadvancedrefractoryradioactiveiodinedifferentiatedthyroidcanceranewchallengefor18ffdgpetct AT santogiulia earlypredictiveresponsetomultityrosinekinaseinhibitorsinadvancedrefractoryradioactiveiodinedifferentiatedthyroidcanceranewchallengefor18ffdgpetct AT rutarossella earlypredictiveresponsetomultityrosinekinaseinhibitorsinadvancedrefractoryradioactiveiodinedifferentiatedthyroidcanceranewchallengefor18ffdgpetct AT lavellivalentina earlypredictiveresponsetomultityrosinekinaseinhibitorsinadvancedrefractoryradioactiveiodinedifferentiatedthyroidcanceranewchallengefor18ffdgpetct AT rubinidino earlypredictiveresponsetomultityrosinekinaseinhibitorsinadvancedrefractoryradioactiveiodinedifferentiatedthyroidcanceranewchallengefor18ffdgpetct AT mammuccipaolo earlypredictiveresponsetomultityrosinekinaseinhibitorsinadvancedrefractoryradioactiveiodinedifferentiatedthyroidcanceranewchallengefor18ffdgpetct AT sardaroangela earlypredictiveresponsetomultityrosinekinaseinhibitorsinadvancedrefractoryradioactiveiodinedifferentiatedthyroidcanceranewchallengefor18ffdgpetct AT rubinigiuseppe earlypredictiveresponsetomultityrosinekinaseinhibitorsinadvancedrefractoryradioactiveiodinedifferentiatedthyroidcanceranewchallengefor18ffdgpetct |